دورية أكاديمية
Corticosteroids, the oldest agent in the prevention of chemotherapy-induced nausea and vomiting: What about the guidelines?
| العنوان: | Corticosteroids, the oldest agent in the prevention of chemotherapy-induced nausea and vomiting: What about the guidelines? |
|---|---|
| المؤلفون: | Van Ryckeghem F; Department of Medical Oncology, Ghent University Hospital, Belgium. |
| المصدر: | Journal of translational internal medicine [J Transl Int Med] 2016 Apr 01; Vol. 4 (1), pp. 46-51. Date of Electronic Publication: 2016 Apr 14. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Sciendo Country of Publication: Poland NLM ID: 101673826 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2450-131X (Print) Linking ISSN: 22244018 NLM ISO Abbreviation: J Transl Int Med Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: [Warsaw, Poland] : Sciendo Original Publication: Hong Kong ; Beijing : Mumbai : Spring Media Publishing ; Medknow Publications and Media, [2013]- |
| مستخلص: | Chemotherapy-induced nausea and vomiting (CINV) remains one of the most disturbing side effects of cancer treatment. Research in antiemetic therapy has progressed gradually since the early eighties, and the development of antiemetic agents continues. This review focuses on the current management of CINV based on the most recent guidelines, and adherence to the latter is examined more carefully. Setrons (5HT3 receptor antagonists), corticosteroids, and NK-1 receptor antagonists are the cornerstones of antiemetic therapy. Corticosteroids are one of the oldest agents in the prevention of CINV. They are highly effective, increase the effect of other antiemetic agents, and are cost-effective. The latest developed 5HT3 receptor antagonist palonosetron led to an update of the guidelines of CINV. Other types include benzodiazepines, cannabinoids, and olanzapine. Various factors contribute to the overall risk of developing CINV, such as patient characteristics, emetogenic potency of the chemotherapeutic agents, and correct prevention of CINV. Current guidelines determine which is the right preventive regimen for each cancer patient at risk for experiencing CINV. Adherence to these guidelines and implementation in daily practice seem to be below the optimal level. In Belgium, authorities use the guidelines as a base for reimbursement and this has increased the level of implementation. Competing Interests: Conflicts of Interest: None declared. |
| References: | Ann Oncol. 2003 Oct;14(10):1570-7. (PMID: 14504060) Support Care Cancer. 2005 Feb;13(2):97-103. (PMID: 15565276) Lancet Oncol. 2009 Jun;10(6):549-58. (PMID: 19428297) Cancer. 2000 Dec 1;89(11):2301-8. (PMID: 11147601) Ann Oncol. 2007 Feb;18(2):233-40. (PMID: 17108149) J Support Oncol. 2006 Feb;4(2 Suppl 1):3-8. (PMID: 16499138) J Natl Cancer Inst. 1997 Jun 4;89(11):817-8. (PMID: 9182982) J Clin Oncol. 2003 Nov 15;21(22):4112-9. (PMID: 14559886) Oncologist. 2003;8(2):187-98. (PMID: 12697943) J Clin Oncol. 2011 Nov 1;29(31):4189-98. (PMID: 21947834) J Clin Oncol. 2009 Nov 10;27(32):5363-9. (PMID: 19805683) Cancer. 2004 May 15;100(10):2261-8. (PMID: 15139073) Br J Cancer. 2006 Apr 10;94(7):1011-5. (PMID: 16552437) Ann Oncol. 2010 May;21 Suppl 5:v232-43. (PMID: 20555089) Support Care Cancer. 2003 Dec;11(12):785-9. (PMID: 14579136) BMJ. 2001 Jul 7;323(7303):16-21. (PMID: 11440936) Drugs. 2004;64(7):777-94. (PMID: 15025555) Eur J Cancer. 2005 Jun;41(9):1278-85. (PMID: 15939263) Eur J Pharmacol. 1993 Nov 2;249(1):R3-4. (PMID: 7506663) J Clin Oncol. 2005 Feb 20;23(6):1289-94. (PMID: 15718327) J Clin Pharmacol. 2004 Mar;44(3):215-23. (PMID: 14973304) Eur J Cancer. 2003 May;39(8):1074-80. (PMID: 12736106) Eur J Cancer Clin Oncol. 1983 Feb;19(2):203-8. (PMID: 6681766) N Engl J Med. 2008 Jun 5;358(23):2482-94. (PMID: 18525044) Support Care Cancer. 2007 Nov;15(11):1285-91. (PMID: 17375339) Lancet Oncol. 2005 Aug;6(8):622-5. (PMID: 16054573) J Clin Oncol. 1985 Oct;3(10):1379-84. (PMID: 4045527) Acta Clin Belg. 2010 Sep-Oct;65(5):305-10. (PMID: 21128556) J Clin Oncol. 2005 Apr 20;23(12):2822-30. (PMID: 15837996) Expert Opin Pharmacother. 2009 Mar;10(4):629-44. (PMID: 19284365) Cancer. 2005 Oct 1;104(7):1548-55. (PMID: 16104039) Expert Opin Pharmacother. 2008 Dec;9(18):3261-70. (PMID: 19040346) |
| فهرسة مساهمة: | Keywords: antiemetic therapy; chemotherapy; guidelines; prevention |
| تواريخ الأحداث: | Date Created: 20170214 Latest Revision: 20200930 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC5290915 |
| DOI: | 10.1515/jtim-2016-0010 |
| PMID: | 28191518 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2450-131X |
|---|---|
| DOI: | 10.1515/jtim-2016-0010 |